Press Releases

Akeso, Inc. is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis. The strategic combination of drugs such as gumokimab and ebronucimab (PCSK9) to address the differentiated treatment needs of psoriasis has further enhanced the company'

of The Nasdaq Stock Market LLC that the Company has rHoth Therapeutics, Inc. a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department egained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The Company received written notification from Nasdaq on January 23, 2025, stating that because the Company's common stock had a closing bid price at or above $1.00 per share for 10 cons

CG Pharmaceuticals, a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity after licensing ivaltinostat from CG Invites. The company has since been conducting various research projects on ivaltinostat in the U.S. including the metastatic pancreatic cancer (mPDAC) clinical trial (NCT05249101). The results of the completed Phase 1b study and the progress report of Phase 2 will be presented at the ASCO Gastrointestinal Symposium on Fr

ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited. Following the closing of this transaction, ImaginAb Inc., will focus on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical

Cytonics Corporation, a private biotechnology company developing cutting-edge biologic therapies for musculoskeletal conditions, today announced that the first nine patients in its Phase 1 clinical trial evaluating CYT-108 as a therapy for osteoarthritis have successfully completed the study. All patients received two intra-articular doses of CYT-108, administered on Day 0 and Day 90, with follow-up extending to Day 180. Importantly, no drug-related adverse events have been reported, undersco

Kyverna Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple therapeutic areas, including immunology, as both an accomplished pha

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4. FZ002-037 is a highly selective oral small-molecule SSTR4 agonist developed by Fermion. Preclinical studies indicate that the drug primarily provides peripheral analgesia without central side effects or addiction risks, making it a promising option for patients requiring long-term pain management. I

Segra International a globally recognized leader in cannabis ag-tech and genetics, is pleased to announce a strategic partnership with GreenBe Pharma, a premier European medicinal cannabis producer. This collaboration enables European cultivators to efficiently access Segra’s renowned tissue culture cannabis clones through a localized European hub, significantly reducing the logistics and regulatory complexities often associated with international imports. Under this arra

Predictive Oncology Inc. a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United States. The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time. The ChemoFx® drug response assay is a treatment sel

Cybin Inc. a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“SPA”) with Segal Trials in furtherance of Cybin’s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). Segal Trials, th